| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 103,357 | 71,271 | ||
| Marketable securities | 49,697 | 1,403 | ||
| Restricted cash | 4,195 | 4,195 | ||
| Prepaid expenses and other current assets | 4,510 | 5,633 | ||
| Total current assets | 161,759 | 82,502 | ||
| Property and equipment, at cost | 83,774 | - | ||
| Less accumulated depreciation | 53,843 | - | ||
| Property and equipment, net | 29,931 | 33,081 | ||
| Operating lease right-of-use assets | 40,704 | 43,021 | ||
| Intangible asset | 59,195 | 59,195 | ||
| Goodwill | 140,627 | 140,627 | ||
| Other non-current assets | 3,216 | 3,219 | ||
| Total assets | 435,432 | 361,645 | ||
| Accounts payable | 1,858 | 2,270 | ||
| Accrued compensation | 11,296 | 9,411 | ||
| Accrued expenses and other current liabilities | 7,991 | 7,931 | ||
| Operating lease liabilities | 14,368 | 13,832 | ||
| Total current liabilities | 35,513 | 33,444 | ||
| Operating lease liabilities, net of current portion | 67,868 | 71,660 | ||
| Contingent consideration | 115,141 | 117,132 | ||
| Success payment liabilities | 13,726 | 8,611 | ||
| Other non-current liabilities | 7,876 | 8,242 | ||
| Total liabilities | 240,124 | 239,089 | ||
| Common stock, 0.0001 par value 750,000 shares authorized 262,264 and 223,923 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 26 | 23 | ||
| Additional paid-in capital | 1,985,452 | 1,870,572 | ||
| Accumulated other comprehensive income | 21 | 0 | ||
| Accumulated deficit | -1,790,191 | -1,748,039 | ||
| Total stockholders' equity | 195,308 | 122,556 | ||
| Total liabilities and stockholders' equity | 435,432 | 361,645 | ||
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)